Detalles de la búsqueda
1.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910338
2.
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Invest New Drugs
; 38(3): 844-854, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31385109
3.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31563517
4.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Cancer
; 125(7): 1113-1123, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30690710
5.
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Lancet Oncol
; 19(1): 51-64, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217288
6.
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
Cancer
; 124(9): 2010-2017, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29469949
7.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): 153-161, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28949957
8.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): e3, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29361630
9.
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Invest New Drugs
; 36(6): 1016-1025, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611022
10.
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Br J Clin Pharmacol
; 84(4): 764-775, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29243287
11.
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Br J Cancer
; 116(5): 575-583, 2017 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152546
12.
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(5): 576-588, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424891
13.
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
BMC Cancer
; 17(1): 173, 2017 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28264648
14.
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Invest New Drugs
; 34(2): 216-24, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26924128
15.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26296952
16.
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Cancer
; 121(7): 1056-63, 2015 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25411085
17.
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Cancer
; 121(19): 3481-90, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26177599
18.
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Oncologist
; 20(2): 143-50, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25582141
19.
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Invest New Drugs
; 33(1): 187-93, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25335932
20.
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 432-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25640850